As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...
Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...
High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...
Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...
Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...
TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...
Clinical Trials Arena on MSN3d
Praxis Precision continues with ET trial despite likely failure warningUS-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...
Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the ...
The "43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025" report has been added to ResearchAndMarkets.com's offering.The 43rd Annual JP Morgan Healthcare Conference took place in San ...
After hours: 7:49:09 p.m. EST ...
Pre-market: 4:36:52 am GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback